Chlorproguanil-dapsone: effective treatment for uncomplicated falciparum malaria

Pyrimethamine-sulfadoxine, the first choice for uncomplicated falciparum malaria in Africa, exerts strong selection pressure for resistance because of its slow elimination. It is likely that resistance will emerge rapidly, and there is no widely affordable replacement. Chlorproguanil-dapsone is chea...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Antimicrobial agents and chemotherapy Ročník 41; číslo 10; s. 2261
Hlavní autori:	Amukoye, E, Winstanley, P A, Watkins, W M, Snow, R W, Hatcher, J, Mosobo, M, Ngumbao, E, Lowe, B, Ton, M, Minyiri, G, Marsh, K
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States 01.10.1997
Predmet:	Antimalarials - therapeutic use Child Child, Preschool Dapsone - therapeutic use Double-Blind Method Drug Combinations Drug Resistance Female Hemoglobins - metabolism Humans Infant Malaria, Falciparum - blood Malaria, Falciparum - drug therapy Malaria, Falciparum - parasitology Male Proguanil - analogs & derivatives Proguanil - therapeutic use Pyrimethamine - therapeutic use Sulfadoxine - therapeutic use
ISSN:	0066-4804
On-line prístup:	Zistit podrobnosti o prístupe
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Abstract	Pyrimethamine-sulfadoxine, the first choice for uncomplicated falciparum malaria in Africa, exerts strong selection pressure for resistance because of its slow elimination. It is likely that resistance will emerge rapidly, and there is no widely affordable replacement. Chlorproguanil-dapsone is cheap, rapidly eliminated, more potent than pyrimethamine-sulfadoxine, and could be introduced in the near future to delay the onset of antifolate resistance and as "salvage therapy" for pyrimethamine-sulfadoxine failure. A total of 448 children were randomly allocated (double blind) to either a single dose of pyrimethamine-sulfadoxine or to one of two chlorproguanil-dapsone regimens: a single dose or three doses at 24-h intervals. Reinfections are clinically indistinguishable from recrudescence and are more likely after treatment with rapidly eliminated drugs; we measured the incidence of parasitemia in 205 initially aparasitemic children to allow comparison with the three treatment groups. The patients and a community surveillance group were followed up for 28 days. At the study end point, 31.2% (95% confidence interval, 24.9-38.0) of the community surveillance group subjects were parasitemic, compared with subjects in the treatment groups, whose rates of parasitemia were 40.8% (32.9-49.0; relative risk [RR], 1.31 [0.99-1.73]) after triple-dose chlorproguanil-dapsone, 19.7% (13.5-27.2; RR, 0.63 [0.43-0.93]) after pyrimethamine-sulfadoxine, and 65.6% (57.5-73.0; RR, 2.10 [1.66-2.65]) after single-dose chlorproguanil-dapsone. Pyrimethamine-sulfadoxine and triple-dose chlorproguanil-dapsone were effective treatments. Pyrimethamine-sulfadoxine provided chemoprophylaxis during follow-up because of its slow elimination. Triple-dose chlorproguanil-dapsone should now be developed in an attempt to reduce the rate of emergence of antifolate resistance in Africa and for affordable salvage therapy in cases of pyrimethamine-sulfadoxine failure.
AbstractList	Pyrimethamine-sulfadoxine, the first choice for uncomplicated falciparum malaria in Africa, exerts strong selection pressure for resistance because of its slow elimination. It is likely that resistance will emerge rapidly, and there is no widely affordable replacement. Chlorproguanil-dapsone is cheap, rapidly eliminated, more potent than pyrimethamine-sulfadoxine, and could be introduced in the near future to delay the onset of antifolate resistance and as "salvage therapy" for pyrimethamine-sulfadoxine failure. A total of 448 children were randomly allocated (double blind) to either a single dose of pyrimethamine-sulfadoxine or to one of two chlorproguanil-dapsone regimens: a single dose or three doses at 24-h intervals. Reinfections are clinically indistinguishable from recrudescence and are more likely after treatment with rapidly eliminated drugs; we measured the incidence of parasitemia in 205 initially aparasitemic children to allow comparison with the three treatment groups. The patients and a community surveillance group were followed up for 28 days. At the study end point, 31.2% (95% confidence interval, 24.9-38.0) of the community surveillance group subjects were parasitemic, compared with subjects in the treatment groups, whose rates of parasitemia were 40.8% (32.9-49.0; relative risk [RR], 1.31 [0.99-1.73]) after triple-dose chlorproguanil-dapsone, 19.7% (13.5-27.2; RR, 0.63 [0.43-0.93]) after pyrimethamine-sulfadoxine, and 65.6% (57.5-73.0; RR, 2.10 [1.66-2.65]) after single-dose chlorproguanil-dapsone. Pyrimethamine-sulfadoxine and triple-dose chlorproguanil-dapsone were effective treatments. Pyrimethamine-sulfadoxine provided chemoprophylaxis during follow-up because of its slow elimination. Triple-dose chlorproguanil-dapsone should now be developed in an attempt to reduce the rate of emergence of antifolate resistance in Africa and for affordable salvage therapy in cases of pyrimethamine-sulfadoxine failure.Pyrimethamine-sulfadoxine, the first choice for uncomplicated falciparum malaria in Africa, exerts strong selection pressure for resistance because of its slow elimination. It is likely that resistance will emerge rapidly, and there is no widely affordable replacement. Chlorproguanil-dapsone is cheap, rapidly eliminated, more potent than pyrimethamine-sulfadoxine, and could be introduced in the near future to delay the onset of antifolate resistance and as "salvage therapy" for pyrimethamine-sulfadoxine failure. A total of 448 children were randomly allocated (double blind) to either a single dose of pyrimethamine-sulfadoxine or to one of two chlorproguanil-dapsone regimens: a single dose or three doses at 24-h intervals. Reinfections are clinically indistinguishable from recrudescence and are more likely after treatment with rapidly eliminated drugs; we measured the incidence of parasitemia in 205 initially aparasitemic children to allow comparison with the three treatment groups. The patients and a community surveillance group were followed up for 28 days. At the study end point, 31.2% (95% confidence interval, 24.9-38.0) of the community surveillance group subjects were parasitemic, compared with subjects in the treatment groups, whose rates of parasitemia were 40.8% (32.9-49.0; relative risk [RR], 1.31 [0.99-1.73]) after triple-dose chlorproguanil-dapsone, 19.7% (13.5-27.2; RR, 0.63 [0.43-0.93]) after pyrimethamine-sulfadoxine, and 65.6% (57.5-73.0; RR, 2.10 [1.66-2.65]) after single-dose chlorproguanil-dapsone. Pyrimethamine-sulfadoxine and triple-dose chlorproguanil-dapsone were effective treatments. Pyrimethamine-sulfadoxine provided chemoprophylaxis during follow-up because of its slow elimination. Triple-dose chlorproguanil-dapsone should now be developed in an attempt to reduce the rate of emergence of antifolate resistance in Africa and for affordable salvage therapy in cases of pyrimethamine-sulfadoxine failure. Pyrimethamine-sulfadoxine, the first choice for uncomplicated falciparum malaria in Africa, exerts strong selection pressure for resistance because of its slow elimination. It is likely that resistance will emerge rapidly, and there is no widely affordable replacement. Chlorproguanil-dapsone is cheap, rapidly eliminated, more potent than pyrimethamine-sulfadoxine, and could be introduced in the near future to delay the onset of antifolate resistance and as "salvage therapy" for pyrimethamine-sulfadoxine failure. A total of 448 children were randomly allocated (double blind) to either a single dose of pyrimethamine-sulfadoxine or to one of two chlorproguanil-dapsone regimens: a single dose or three doses at 24-h intervals. Reinfections are clinically indistinguishable from recrudescence and are more likely after treatment with rapidly eliminated drugs; we measured the incidence of parasitemia in 205 initially aparasitemic children to allow comparison with the three treatment groups. The patients and a community surveillance group were followed up for 28 days. At the study end point, 31.2% (95% confidence interval, 24.9-38.0) of the community surveillance group subjects were parasitemic, compared with subjects in the treatment groups, whose rates of parasitemia were 40.8% (32.9-49.0; relative risk [RR], 1.31 [0.99-1.73]) after triple-dose chlorproguanil-dapsone, 19.7% (13.5-27.2; RR, 0.63 [0.43-0.93]) after pyrimethamine-sulfadoxine, and 65.6% (57.5-73.0; RR, 2.10 [1.66-2.65]) after single-dose chlorproguanil-dapsone. Pyrimethamine-sulfadoxine and triple-dose chlorproguanil-dapsone were effective treatments. Pyrimethamine-sulfadoxine provided chemoprophylaxis during follow-up because of its slow elimination. Triple-dose chlorproguanil-dapsone should now be developed in an attempt to reduce the rate of emergence of antifolate resistance in Africa and for affordable salvage therapy in cases of pyrimethamine-sulfadoxine failure.
Author	Lowe, B Snow, R W Ton, M Minyiri, G Amukoye, E Marsh, K Mosobo, M Watkins, W M Hatcher, J Ngumbao, E Winstanley, P A
Author_xml	– sequence: 1 givenname: E surname: Amukoye fullname: Amukoye, E organization: Kilifi Research Unit, Kenya Medical Research Institute – sequence: 2 givenname: P A surname: Winstanley fullname: Winstanley, P A – sequence: 3 givenname: W M surname: Watkins fullname: Watkins, W M – sequence: 4 givenname: R W surname: Snow fullname: Snow, R W – sequence: 5 givenname: J surname: Hatcher fullname: Hatcher, J – sequence: 6 givenname: M surname: Mosobo fullname: Mosobo, M – sequence: 7 givenname: E surname: Ngumbao fullname: Ngumbao, E – sequence: 8 givenname: B surname: Lowe fullname: Lowe, B – sequence: 9 givenname: M surname: Ton fullname: Ton, M – sequence: 10 givenname: G surname: Minyiri fullname: Minyiri, G – sequence: 11 givenname: K surname: Marsh fullname: Marsh, K
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/9333058$$D View this record in MEDLINE/PubMed
BookMark	eNotkE1LAzEYhHOo1LZ69SbsydvWfO1HvUmxKhT0oOflTfJGI8nummQF_70L9jTM8DAMsyaLfuiRkCtGt4zx9hZAbyXbzpbzmi3IitK6LmVL5TlZp_RFZ1_t6JIsd0IIWrUr8rr_9EMc4_AxQe98aWBMc-ldgdaizu4HixwRcsA-F3aIxdTrIYzeachoCgteuxHiFIoAHqKDC3I2hwkvT7oh74eHt_1TeXx5fN7fH0uoaJNLYSmibCRDY5hSqkLDhW3Baip4UxmjWmUBFBXGWkG55C3UrGLSMOTMAN-Qm__eefv3hCl3wSWN3kOPw5S6Zie4qGs5g9cncFIBTTdGFyD-dqcL-B-97V_j
CitedBy_id	crossref_primary_10_1016_S0166_6851_97_00114_X crossref_primary_10_1097_00001432_199912000_00008 crossref_primary_10_1128_AAC_01835_15 crossref_primary_10_1179_136485905X51274 crossref_primary_10_1128_AAC_42_1_164 crossref_primary_10_1016_S0957_5839_99_90023_4 crossref_primary_10_1186_s12936_017_1937_2 crossref_primary_10_1146_annurev_pharmtox_45_120403_095946 crossref_primary_10_1016_j_actatropica_2005_06_018 crossref_primary_10_1208_s12249_024_02935_2 crossref_primary_10_1016_S0035_9203_01_90331_1 crossref_primary_10_1016_S0140_6736_01_06344_9 crossref_primary_10_1093_bmb_62_1_59 crossref_primary_10_1016_S0169_4758_99_01622_1 crossref_primary_10_1086_588198 crossref_primary_10_1128_AAC_44_4_991_996_2000 crossref_primary_10_2165_00003088_200140050_00003 crossref_primary_10_1046_j_1365_3156_1999_00361_x crossref_primary_10_1517_13543776_11_8_1285 crossref_primary_10_1016_S0020_7519_02_00164_9 crossref_primary_10_1016_S1471_4922_01_02085_2 crossref_primary_10_1371_journal_pone_0128792 crossref_primary_10_1016_j_trstmh_2004_07_002 crossref_primary_10_1371_journal_pone_0116856 crossref_primary_10_1016_j_exppara_2009_01_009 crossref_primary_10_1016_j_actatropica_2006_01_005 crossref_primary_10_1016_j_molbiopara_2004_09_005 crossref_primary_10_1016_S1471_4922_01_02185_7 crossref_primary_10_1016_S0035_9203_99_90083_4 crossref_primary_10_1016_S1368_7646_98_80014_9 crossref_primary_10_1186_1475_2875_8_106 crossref_primary_10_1016_S0035_9203_99_90158_X crossref_primary_10_1016_S0166_6851_01_00335_8 crossref_primary_10_1186_s12936_016_1172_2 crossref_primary_10_1016_S0035_9203_03_80038_X crossref_primary_10_1046_j_1365_3156_2001_00751_x crossref_primary_10_1016_S0035_9203_01_90207_X crossref_primary_10_1073_pnas_182295999 crossref_primary_10_1016_S0014_4894_02_00108_X crossref_primary_10_1016_S0166_6851_98_00075_9 crossref_primary_10_1517_13543784_7_2_261 crossref_primary_10_1016_S1201_9712_02_90156_6 crossref_primary_10_1046_j_1365_3156_2003_01066_x crossref_primary_10_1016_S0140_6736_02_11198_6 crossref_primary_10_3390_ijms24010057 crossref_primary_10_1016_S0140_6736_04_16350_2 crossref_primary_10_1016_S1473_3099_03_00547_4
ContentType	Journal Article
DBID	CGR CUY CVF ECM EIF NPM 7X8
DOI	10.1128/aac.41.10.2261
DatabaseName	Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic
DatabaseTitle	MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE - Academic MEDLINE
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	no_fulltext_linktorsrc
Discipline	Medicine Biology Pharmacy, Therapeutics, & Pharmacology
ExternalDocumentID	9333058
Genre	Clinical Trial Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article
GrantInformation_xml	– fundername: Wellcome Trust
GroupedDBID	--- .55 .GJ 0R~ 23M 2WC 39C 3O- 4.4 53G 5GY 5RE 5VS 6J9 ACGFO ADBBV AENEX AGNAY AGVNZ AI. ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BTFSW C1A CGR CS3 CUY CVF DIK E3Z EBS ECM EIF EJD F5P FRP GX1 H13 HH5 HYE HZ~ H~9 J5H K-O KQ8 L7B LSO MVM NEJ NPM O9- OK1 P2P RHF RHI RNS RPM RSF TR2 UHB VH1 W2D W8F WH7 WHG WOQ X7M X7N XOL Y6R ZGI ZXP ~A~ 7X8 AAGFI
ID	FETCH-LOGICAL-a507t-3f0ee4741edd1bbb5ed23f8afc03275ddb8bfaab03dff302428a61514d1e21da2
IEDL.DBID	7X8
ISICitedReferencesCount	69
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=10.1128/AAC.41.10.2261&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	0066-4804
IngestDate	Thu Sep 04 16:46:17 EDT 2025 Sat Sep 28 07:39:43 EDT 2024
IsDoiOpenAccess	false
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	10
Language	English
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-a507t-3f0ee4741edd1bbb5ed23f8afc03275ddb8bfaab03dff302428a61514d1e21da2
Notes	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Undefined-3
OpenAccessLink	https://aac.asm.org/content/aac/41/10/2261.full.pdf
PMID	9333058
PQID	79323664
PQPubID	23479
ParticipantIDs	proquest_miscellaneous_79323664 pubmed_primary_9333058
PublicationCentury	1900
PublicationDate	1997-10-01
PublicationDateYYYYMMDD	1997-10-01
PublicationDate_xml	– month: 10 year: 1997 text: 1997-10-01 day: 01
PublicationDecade	1990
PublicationPlace	United States
PublicationPlace_xml	– name: United States
PublicationTitle	Antimicrobial agents and chemotherapy
PublicationTitleAlternate	Antimicrob Agents Chemother
PublicationYear	1997
References	8665377 - Trop Med Int Health. 1996 Apr;1(2):139-46 3068855 - Trans R Soc Trop Med Hyg. 1988;82(3):398-403 9231209 - Trans R Soc Trop Med Hyg. 1997 May-Jun;91(3):322-7 8337731 - Trans R Soc Trop Med Hyg. 1993 Mar-Apr;87(2):207-10 1544746 - Int J Epidemiol. 1992 Feb;21(1):146-54 7610432 - Soc Sci Med. 1995 May;40(9):1271-7 8450258 - J Infect Dis. 1993 Apr;167(4):932-7 8041761 - Proc Natl Acad Sci U S A. 1994 Jul 19;91(15):7149-53 8684102 - Lancet. 1996 Jun 1;347(9014):1511-4 8531544 - Lancet. 1996 Jan 6;347(8993):2-3 6662888 - J Chromatogr. 1983 Nov 11;278(1):81-9 2663650 - Gene. 1989 Mar 15;76(1):41-52 7925353 - Eur J Biochem. 1994 Sep 1;224(2):397-405 3076997 - Trans R Soc Trop Med Hyg. 1988;82(6):833-7 1550695 - Br J Clin Pharmacol. 1992 Feb;33(2):143-8 8940973 - Am J Trop Med Hyg. 1996 Nov;55(5):467-71 8249058 - Trans R Soc Trop Med Hyg. 1993 Jul-Aug;87(4):386-90 8465404 - Trans R Soc Trop Med Hyg. 1993 Jan-Feb;87(1):75-8 2884288 - J Pharm Pharmacol. 1987 Apr;39(4):261-5 2183221 - Proc Natl Acad Sci U S A. 1990 Apr;87(8):3014-7 7786001 - Antimicrob Agents Chemother. 1995 Apr;39(4):948-52 2274577 - Pharmacol Ther. 1990;48(1):45-59 2183222 - Proc Natl Acad Sci U S A. 1990 Apr;87(8):3018-22
References_xml	– reference: 2183221 - Proc Natl Acad Sci U S A. 1990 Apr;87(8):3014-7 – reference: 8940973 - Am J Trop Med Hyg. 1996 Nov;55(5):467-71 – reference: 7786001 - Antimicrob Agents Chemother. 1995 Apr;39(4):948-52 – reference: 8531544 - Lancet. 1996 Jan 6;347(8993):2-3 – reference: 2884288 - J Pharm Pharmacol. 1987 Apr;39(4):261-5 – reference: 8337731 - Trans R Soc Trop Med Hyg. 1993 Mar-Apr;87(2):207-10 – reference: 8450258 - J Infect Dis. 1993 Apr;167(4):932-7 – reference: 9231209 - Trans R Soc Trop Med Hyg. 1997 May-Jun;91(3):322-7 – reference: 3076997 - Trans R Soc Trop Med Hyg. 1988;82(6):833-7 – reference: 7925353 - Eur J Biochem. 1994 Sep 1;224(2):397-405 – reference: 2663650 - Gene. 1989 Mar 15;76(1):41-52 – reference: 1544746 - Int J Epidemiol. 1992 Feb;21(1):146-54 – reference: 8665377 - Trop Med Int Health. 1996 Apr;1(2):139-46 – reference: 8465404 - Trans R Soc Trop Med Hyg. 1993 Jan-Feb;87(1):75-8 – reference: 8684102 - Lancet. 1996 Jun 1;347(9014):1511-4 – reference: 2274577 - Pharmacol Ther. 1990;48(1):45-59 – reference: 1550695 - Br J Clin Pharmacol. 1992 Feb;33(2):143-8 – reference: 8249058 - Trans R Soc Trop Med Hyg. 1993 Jul-Aug;87(4):386-90 – reference: 8041761 - Proc Natl Acad Sci U S A. 1994 Jul 19;91(15):7149-53 – reference: 7610432 - Soc Sci Med. 1995 May;40(9):1271-7 – reference: 6662888 - J Chromatogr. 1983 Nov 11;278(1):81-9 – reference: 3068855 - Trans R Soc Trop Med Hyg. 1988;82(3):398-403 – reference: 2183222 - Proc Natl Acad Sci U S A. 1990 Apr;87(8):3018-22
SSID	ssj0006590
Score	1.8223802
Snippet	Pyrimethamine-sulfadoxine, the first choice for uncomplicated falciparum malaria in Africa, exerts strong selection pressure for resistance because of its slow...
SourceID	proquest pubmed
SourceType	Aggregation Database Index Database
StartPage	2261
SubjectTerms	Antimalarials - therapeutic use Child Child, Preschool Dapsone - therapeutic use Double-Blind Method Drug Combinations Drug Resistance Female Hemoglobins - metabolism Humans Infant Malaria, Falciparum - blood Malaria, Falciparum - drug therapy Malaria, Falciparum - parasitology Male Proguanil - analogs & derivatives Proguanil - therapeutic use Pyrimethamine - therapeutic use Sulfadoxine - therapeutic use
Title	Chlorproguanil-dapsone: effective treatment for uncomplicated falciparum malaria
URI	https://www.ncbi.nlm.nih.gov/pubmed/9333058 https://www.proquest.com/docview/79323664
Volume	41
WOSCitedRecordID	wos10.1128/AAC.41.10.2261&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings	1
isFullTextHit
isPrint
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LSwMxEB5848VHVazPHMSTsbub7EsEKcXipWUPCr2VZJNgod1WtxX6753sw57Eg5e9LYTJ8M03yZdvAG64L5WKuaKR8EPKXR3SGHshymLBeRzxONCyGDYR9vvRYBAna_BYv4WxssoaEwugVtPUnpG3MI88FgT8afZB7cwoe7daDdBYh02GRMYKusLByis88MsTFiyqlEcOrywbEZBb7Xbnnrv3VgftBe7v5LIoMt39_y3vAPYqcknaZTYcwprOGrBdjptcNmCnV12kN-A2KS2rl3fkdfUCK78jtyRZmVkvjyDpvGNHb1VcC5GNxlQJKx_RD6QUgiBWkh-tOkECTLBO1ip1rYgRYyva_lxMyERgEz0Sx_DWfX7tvNBqCgMVyBXnlBlHa47EQyvlSil9rTxmImFSh3mhr5SMpBFCOkwZw2zJj4SlSVy52nOV8E5gI8OFnQKxAZJceGnsae77geSOwf5ScZkai8pNuK6DO8Qst1cXItPTRT6sw9uEk3J_hrPSjGMYM4aQFZ39-es57BbWs4UQ7wI2MQC5voSt9Gs-yj-vitzBbz_pfQPMQc_N
linkProvider	ProQuest
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Chlorproguanil-dapsone%3A+effective+treatment+for+uncomplicated+falciparum+malaria&rft.jtitle=Antimicrobial+agents+and+chemotherapy&rft.au=Amukoye%2C+E&rft.au=Winstanley%2C+P+A&rft.au=Watkins%2C+W+M&rft.au=Snow%2C+R+W&rft.date=1997-10-01&rft.issn=0066-4804&rft.volume=41&rft.issue=10&rft.spage=2261&rft_id=info:doi/10.1128%2FAAC.41.10.2261&rft.externalDBID=NO_FULL_TEXT
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0066-4804&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0066-4804&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0066-4804&client=summon